See more : Audio Pixels Holdings Limited (AKP.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Opthea Limited (OPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Opthea Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Stanley Electric Co., Ltd. (STAEF) Income Statement Analysis – Financial Results
- Lithium Americas Corp. (LAC.TO) Income Statement Analysis – Financial Results
- Anik Industries Limited (ANIKINDS.BO) Income Statement Analysis – Financial Results
- Immunovant, Inc. (IMVT) Income Statement Analysis – Financial Results
- PeakBirch Commerce Inc. (PKB.CN) Income Statement Analysis – Financial Results
Opthea Limited (OPT)
About Opthea Limited
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 124.67K | 161.16K | 125.05K | 91.98K | 145.90K | 112.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.35K | 19.13K | 0.00 | 13.34K | 12.24K | 0.00 | 9.57K | 0.00 | 0.00 | 2.94B | 192.74K | 240.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 250.47K | 232.47K | 571.98K | 517.26K | 273.94K | 28.66K | 26.61K | 30.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 124.67K | -89.31K | -107.42K | -480.00K | -371.37K | -161.45K | -28.66K | -26.61K | -30.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.35K | 19.13K | 0.00 | 13.34K | 12.24K | 0.00 | 9.57K | 0.00 | -27.35K | 2.94B | 192.74K | 240.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 100.00% | -55.42% | -85.91% | -521.85% | -254.54% | -143.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 176.33M | 181.56M | 108.46M | 34.71M | 17.48M | 31.35M | 24.89M | 4.84M | 3.58M | 4.28M | 3.40M | 3.14M | 3.68M | 7.02M | 3.65M | 3.62M | 3.27M | 2.67M | 1.20M | 533.75K | 349.78K | 106.50K | 144.69K | 553.00K | 186.15K | 358.33K | 600.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.67K | 0.00 | 0.00 |
General & Administrative | 15.49M | 19.27M | 16.30M | 11.88M | 6.61M | 5.09M | 2.70M | 3.25M | 2.86M | 2.36M | 2.65M | 3.11M | 3.58M | 4.36M | 4.57M | 3.77M | 3.44M | 3.39M | 2.04M | 1.65M | 1.34M | 1.32M | 1.16M | 1.88M | 320.84K | 332.21K | 0.00 | 252.31K | 204.75K | 132.10K | 113.26K | 74.82K | 43.33K | 59.82K | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 22.63M | 8.52M | 6.54M | 43.14K | 108.90K | 2.29M | 629.16K | 613.02K | 359.30K | 477.17K | 538.63K | 467.15K | 713.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 15.49M | 41.90M | 24.83M | 18.42M | 6.65M | 5.20M | 4.99M | 5.03M | 4.47M | 2.36M | 2.65M | 3.11M | 3.58M | 4.36M | 4.57M | 3.77M | 3.44M | 3.39M | 2.04M | 1.65M | 1.34M | 1.32M | 1.16M | 1.88M | 320.84K | 332.21K | 0.00 | 252.31K | 204.75K | 132.10K | 113.26K | 74.82K | 43.33K | 59.82K | 0.00 | 0.00 |
Other Expenses | 152.46K | 12.30M | 0.00 | 0.00 | 0.00 | 56.76K | 2.03K | 1.23K | 6.23K | 48.00K | 183.04K | 29.55K | 199.06K | 78.32K | 2.12K | 106.79K | 5.76K | 130.52K | 50.38K | 22.90M | 5.33M | 11.79K | 96.84K | 875.00K | 1.59M | 2.79M | 73.54K | 81.79K | 11.03K | 47.58K | 432.57K | 9.00K | 10.00K | 20.00K | 10.00K | 4.53K |
Operating Expenses | 191.97M | 223.46M | 133.29M | 53.13M | 24.71M | 36.27M | 29.88M | 9.87M | 8.05M | 6.80M | 6.59M | 6.88M | 8.90M | 12.27M | 8.68M | 8.46M | 8.26M | 14.38M | 3.55M | 2.32M | 1.80M | 2.94M | 1.32M | 12.76K | 520.09K | 14.89M | 13.11K | 6.78K | 208.69K | 135.65K | 114.72K | 74.82K | 44.07K | 68.25K | 7.93K | -7.55K |
Cost & Expenses | 191.97M | 223.61M | 133.40M | 53.27M | 25.23M | 36.54M | 29.91M | 9.90M | 8.08M | 6.80M | 6.59M | 6.88M | 8.90M | 12.27M | 8.68M | 8.46M | 8.26M | 14.38M | 3.55M | 2.32M | 1.80M | 2.94M | 1.32M | 12.76K | 547.44K | 14.89M | 13.11K | 6.78K | 208.69K | 135.65K | 114.72K | 74.82K | 44.07K | 68.25K | 7.93K | -7.55K |
Interest Income | 3.39M | 4.80M | 324.70K | 498.70K | 696.18K | 755.78K | 735.70K | 384.35K | 325.57K | 324.56K | 258.85K | 530.99K | 998.39K | 1.48M | 1.39M | 1.86M | 3.12M | 1.73M | 815.55K | 1.14M | 617.15K | 569.19K | 579.33K | 1.59M | 326.53K | 106.45K | 72.52K | 158.75K | 82.69K | 54.69K | 36.54K | 7.35K | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 30.26M | 20.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 576.11K | 0.00 | 391.82K | 0.00 | 0.00 | 71.87K | 179.45K | 0.00 | 0.00 | 1.13K | 8.16K | 0.00 | 0.00 | 1.98M | 1.40M | 787.50 | 1.42K | 1.46K | 668.00 | 2.24K | 5.37K | 3.97K | 7.55K | |
Depreciation & Amortization | 103.03K | 150.49K | 108.08K | 143.00K | 144.02K | 33.09K | 28.66K | 26.61K | 30.79K | 29.58K | 35.98K | 24.95K | 29.25K | 30.02K | 24.30K | 27.49K | 29.98K | 25.42K | 13.69K | 23.86K | 26.59K | 0.00 | 16.33K | 12.76K | 13.10K | 14.89M | 13.11K | 6.78K | 3.94K | 3.55K | 1.46K | -273.21K | 747.00 | 766.90 | 7.93K | -7.55K |
EBITDA | -200.02M | -223.30M | -133.16M | -52.85M | -24.92M | -36.64M | -29.74M | -9.80M | -7.72M | -8.08M | -6.81M | -6.54M | -7.45M | -11.05M | -9.63M | -9.24M | -8.22M | -37.88M | -4.41M | 21.89M | -2.54M | -2.94M | -3.22M | -807.30K | -534.34K | 2.94B | 192.74K | 240.51K | -967.05K | -522.00K | -78.92K | -348.03K | -72.46K | -163.35K | -627.42K | -511.89K |
EBITDA Ratio | -160,443.72% | -138,554.61% | -106,489.56% | -57,660.19% | -16,914.89% | -32,565.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -87,982.98% | -198,006.39% | 0.00% | 132,162.03% | -14,580.37% | 0.00% | -33,605.88% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -191.84M | -223.45M | -133.27M | -53.18M | -24.70M | -36.67M | -29.91M | -9.90M | -8.08M | -7.00M | -6.29M | -7.25M | -8.95M | -11.23M | -10.17M | -7.57M | -12.66M | -37.90M | -3.92M | 17.61M | -1.81M | -2.97M | -3.25M | -833.02K | -547.44K | -741.67K | -1.23M | -1.06M | -970.99K | -525.55K | -80.38K | -74.82K | -73.21K | -164.12K | -635.35K | -504.34K |
Operating Income Ratio | -153,885.37% | -138,647.99% | -106,575.99% | -57,815.66% | -16,929.71% | -32,595.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -88,191.87% | -198,139.25% | 0.00% | 131,983.17% | -14,797.71% | 0.00% | -33,943.71% | 0.00% | 0.00% | -0.03% | -638.09% | -439.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -37.81M | -70.67M | -3.41M | -14.23M | 310.76K | 1.03M | 2.98M | 535.06K | -16.02K | 2.24M | 1.16M | 958.26K | 1.72M | 855.19K | 1.17M | -1.70M | 7.18M | 24.55M | -661.28K | -1.01M | 5.87M | 495.02K | -1.92M | -8.17K | 1.28M | 2.32M | -771.54K | -1.04M | 81.90K | 53.27K | 35.07K | -266.53K | 12.70K | 25.31K | 142.78K | 93.62K |
Income Before Tax | -229.65M | -220.69M | -136.68M | -67.41M | -24.39M | -35.55M | -28.92M | -9.36M | -8.10M | -6.23M | -6.45M | -5.99M | -7.48M | -11.80M | -5.81M | -7.97M | -1.07M | 10.19M | -4.58M | 16.60M | 4.06M | -2.45M | -3.23M | -828.22K | 730.42K | 1.58M | -1.23M | -1.06M | -889.09K | -472.28K | -45.30K | -341.35K | -60.51K | -138.81K | -492.58K | -410.72K |
Income Before Tax Ratio | -184,215.67% | -136,936.62% | -109,300.18% | -73,285.73% | -16,716.71% | -31,598.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,445.89% | 53,289.60% | 0.00% | 124,394.23% | 33,158.07% | 0.00% | -33,788.24% | 0.00% | 0.00% | 0.05% | -638.09% | -439.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | -9.41M | -8.81M | -8.69M | -6.62M | 8.27M | 14.64M | -12.02M | -3.17M | -1.57M | -2.09M | -2.69M | -1.42M | -2.46M | -831.43K | 93.06K | 37.02K | 1.12M | 4.85M | 252.37K | 2.79K | -5.87M | -83.76K | 85.58 | -39.80K | -1.28M | 2.37M | -1.98M | -1.40M | -1.13M | -665.00K | -62.00K | -511.00K | -81.00K | -181.00K | -621.00K | -544.00K |
Net Income | -220.24M | -211.88M | -127.99M | -60.79M | -16.12M | -20.91M | -16.90M | -6.19M | -6.51M | -4.07M | -3.76M | -4.34M | -4.95M | -10.97M | -5.91M | -8.00M | -1.10M | 9.50M | -4.80M | 16.60M | 4.06M | -2.36M | -3.23M | -801.17K | 730.42K | 1.58B | -1.23M | -1.05M | -857.59K | -472.28K | -45.30K | -341.35K | -60.51K | -138.81K | -492.58K | -410.72K |
Net Income Ratio | -176,665.73% | -131,469.80% | -102,353.69% | -66,087.58% | -11,047.04% | -18,587.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,652.13% | 49,675.59% | 0.00% | 124,404.80% | 33,158.07% | 0.00% | -33,788.24% | 0.00% | 0.00% | 53.84% | -638.09% | -438.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -2.77 | -0.45 | -0.34 | -0.18 | -0.06 | -0.09 | -0.07 | -0.03 | -0.04 | -0.04 | -0.07 | -0.09 | -0.10 | -0.23 | -0.13 | -0.18 | -0.03 | 0.23 | -0.12 | 0.40 | 0.10 | -0.06 | -0.08 | -0.02 | 0.02 | 48.81 | -0.03 | -0.03 | -0.03 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
EPS Diluted | -2.77 | -0.45 | -0.34 | -0.18 | -0.06 | -0.09 | -0.07 | -0.03 | -0.04 | -0.04 | -0.07 | -0.09 | -0.10 | -0.23 | -0.13 | -0.18 | -0.03 | 0.23 | -0.12 | 0.40 | 0.10 | -0.06 | -0.08 | -0.02 | 0.02 | 48.81 | -0.03 | -0.03 | -0.03 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Weighted Avg Shares Out | 79.78M | 469.56M | 372.94M | 339.92M | 260.50M | 232.80M | 232.17M | 185.69M | 172.99M | 115.73M | 52.78M | 48.57M | 47.61M | 47.32M | 46.29M | 45.65M | 41.05M | 41.32M | 41.05M | 41.05M | 41.10M | 42.24M | 42.20M | 41.83M | 33.62M | 32.42M | 35.49M | 36.12M | 27.17M | 26.07M | 25.37M | 24.51M | 22.31M | 232.80M | 232.80M | 232.80M |
Weighted Avg Shares Out (Dil) | 79.78M | 469.56M | 372.94M | 339.92M | 260.80M | 232.80M | 232.17M | 185.69M | 172.99M | 115.73M | 52.78M | 49.71M | 47.61M | 47.32M | 46.29M | 45.65M | 41.05M | 41.32M | 41.05M | 41.05M | 41.10M | 42.24M | 42.20M | 41.83M | 33.62M | 32.42M | 35.49M | 36.12M | 27.17M | 26.07M | 25.37M | 24.51M | 22.31M | 232.80M | 232.80M | 232.80M |
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
Opthea Appoints Sujal Shah to the Board of Directors
7 Growth Stocks to Buy to Outperform the Nasdaq Index
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
Opthea to Participate in the Leerink Partners Global Biopharma Conference
Opthea Reports Half-Year Financial Results and Business Updates
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
Opthea Strengthens Team with Key Clinical and Regulatory Hires
Opthea to Receive US$35M Commitment and Additional US$50M Funding
Source: https://incomestatements.info
Category: Stock Reports